Greenleaf Trust raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.5% during the 4th quarter, HoldingsChannel reports. The fund owned 112,101 shares of the medical equipment provider’s stock after purchasing an additional 1,675 shares during the period. Greenleaf Trust’s holdings in Hologic were worth $4,792,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Sentry Investment Management LLC lifted its holdings in shares of Hologic by 1.9% during the 2nd quarter. Sentry Investment Management LLC now owns 18,491 shares of the medical equipment provider’s stock valued at $839,000 after buying an additional 353 shares during the last quarter. Creative Planning lifted its holdings in shares of Hologic by 8.2% during the 4th quarter. Creative Planning now owns 15,396 shares of the medical equipment provider’s stock valued at $658,000 after buying an additional 1,161 shares during the last quarter. AT Bancorp lifted its holdings in shares of Hologic by 2.2% during the 4th quarter. AT Bancorp now owns 62,329 shares of the medical equipment provider’s stock valued at $2,664,000 after buying an additional 1,323 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in shares of Hologic by 0.3% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 406,630 shares of the medical equipment provider’s stock valued at $14,919,000 after buying an additional 1,351 shares during the last quarter. Finally, Norinchukin Bank The lifted its holdings in shares of Hologic by 7.4% during the 3rd quarter. Norinchukin Bank The now owns 20,876 shares of the medical equipment provider’s stock valued at $766,000 after buying an additional 1,445 shares during the last quarter. Institutional investors and hedge funds own 93.84% of the company’s stock.

Shares of Hologic, Inc. (NASDAQ HOLX) opened at $37.80 on Wednesday. Hologic, Inc. has a 1-year low of $35.33 and a 1-year high of $46.80. The company has a quick ratio of 0.98, a current ratio of 1.25 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $10,519.17, a P/E ratio of 9.97, a P/E/G ratio of 1.72 and a beta of 0.77.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.05. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The firm had revenue of $791.10 million during the quarter, compared to analyst estimates of $785.80 million. During the same period in the previous year, the company earned $0.52 EPS. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. analysts predict that Hologic, Inc. will post 2.25 earnings per share for the current year.

Several brokerages have recently issued reports on HOLX. Canaccord Genuity reiterated a “buy” rating and set a $48.00 price target on shares of Hologic in a report on Friday, February 9th. Stifel Nicolaus lowered Hologic from a “buy” rating to a “hold” rating and reduced their price target for the company from $45.00 to $42.00 in a report on Friday, February 9th. Needham & Company LLC reiterated a “buy” rating and set a $50.00 price target on shares of Hologic in a report on Friday, February 9th. Zacks Investment Research upgraded Hologic from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a report on Tuesday. Finally, Royal Bank of Canada reiterated a “hold” rating and set a $44.00 price target on shares of Hologic in a report on Friday, February 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Hologic currently has a consensus rating of “Buy” and a consensus target price of $48.00.

In related news, VP Karleen Marie Oberton sold 1,023 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.88% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “Hologic, Inc. (HOLX) Shares Bought by Greenleaf Trust” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://theolympiareport.com/2018/02/14/hologic-inc-holx-shares-bought-by-greenleaf-trust.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.